Vol 3 | Issue 2 | Sep-Dec 2017 | page:1 | Dr. Mandip Shah.
Author: Mandip Shah .
 Sparsh Orthopedic Oncology Clinic. Medicare Building 9th Floor, , B/H Town Hall, Ashram Road, 380006 – Ahmedabad., India.
Address of Correspondence
Dr. Mandip Shah
Sparsh Orthopedic Oncology Clinic. Medicare Building 9th Floor, , B/H Town Hall, Ashram Road, 380006 – Ahmedabad., India
Giant Cell Tumor Symposium Part 2
We are back with the second part of the Giant Cell Tumor Symposium for Journal of Bone and Soft Tissue Tumors.
Two very important aspects are covered in this part. First is the histopathological concepts regarding GCT. There is lot of new knowledge that is available in recent years and that has significantly impacted the diagnosis, management and prognosis of GCT. Histopathological assessment play a major role in terms of determining the behaviour of GCT. Current understanding of molecular pathogenesis of GCTB particularly RANK on osteoclast-like GCs and RANKL on stromal cells and development of newer agents such as denosumab and INF-α has tremendously impacted management of patients with GCTB. This aspect is elaborated in the first article. The second article builds on these concepts and describes how this is used for adjuvent therapy for GCTB. Authors of both the authors have taken tremendous effort to make both these articles good and current. Also these two now conclude the GCT Symposium and cover all aspect of GCTB
Please write to us regarding your suggestions and opinions
Dr. Mandip Shah
|How to Cite this article: Shah M. Giant Cell Tumor Symposium Part 2. Journal of Bone and Soft Tissue Tumors Sep-Dec 2017; 3(2):1.|